Microbia and Teva expand partnership
US-based Microbia has announced a multiyear, multiproduct expansion of its collaboration with Teva Pharmaceutical Industries to develop improved, higher-yielding biomanufacturing processes using Microbia's Precision Engineering technology.
US-based Microbia has announced a multiyear, multiproduct expansion of its collaboration with Teva Pharmaceutical Industries to develop improved, higher-yielding biomanufacturing processes using Microbia's Precision Engineering technology.
Under the agreement, Teva will fund Microbia's efforts and make undisclosed milestone and royalty payments based on success. Specific terms were not disclosed.
Precision Engineering is a comprehensive approach to engineering microbial production systems that delivers improved manufacturing economics for existing processes or creates novel processes to enable entry into new markets. Applications address the pharmaceutical and chemical markets. Benefits include reduced process-improvement cycle time and the ability to increase production capacity with minimal capital expenditure, claims Microbia.
The companies have collaborated on improving biomanufacturing processes for Teva products since February 2002.